Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

(2017) Kenichi Suda et al.   Journal of Thoracic Oncology

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

(2017) Chao-Chi Ho et al.   Journal of Thoracic Oncology

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

(2016) S. Ortiz-Cuaran et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

(2016) Ying Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

(2016) Alessandra Fabi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation

(2016) Silvia La Monica et al.   Journal of Thoracic Oncology

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

(2016) Melissa Bersanelli et al.   Journal of Thoracic Oncology

Targeting microenvironment in cancer therapeutics

(2016) Matthew Martin et al.   Oncotarget

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

(2015) D. Planchard et al.   ANNALS OF ONCOLOGY

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR

(2015) M. Watanabe et al.   CLINICAL CANCER RESEARCH

Targeting HER2 in the treatment of non-small cell lung cancer

(2015) Nataliya Mar et al.   LUNG CANCER

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations

(2015) M. A. Bonelli et al.   MOLECULAR CANCER THERAPEUTICS

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

(2014) Daniele Cretella et al.   Molecular Cancer

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification

(2013) Silvia La Monica et al.   PLoS One

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

(2012) Andrea Cavazzoni et al.   Molecular Cancer

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

(2009) Silvia La Monica et al.   BIOCHEMICAL PHARMACOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

(2008) A. Cavazzoni et al.   MOLECULAR CANCER THERAPEUTICS

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE